Cyberounds Logo
September 23, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Inflammatory Breast Cancer
CME credit is no longer available for this conference.
Robert G. Lerner, M.D.

In the past three years, Dr. Lerner has served as a consultant for RPR, and has served on the Speakers' Bureau for Pharmacia & Upjohn.


Release Date: 09/29/2002
Termination Date: 09/29/2005

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the clinicopathologic entity of inflammatory breast cancer
  • Discuss the prognosis for women with inflammatory breast cancer
  • Explain the dramatic improvement in prognosis since the introduction of modern combined modality therapy
  • Discuss the availability of and controversy surrounding the use of autologous bone marrow transplantation for breast cancer.

 
This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity